Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma
AIM: We wanted to assess the potency of a trifunctional nanoparticle (NP) that targeted and activated CD8+ dendritic cells (DC) and delivered an antigen to induce antitumor responses.
MATERIALS & METHODS: The DC targeting and activating properties of ferrous NPs conjugated with immunostimulatory CpG-oligonucleotides, anti-DEC205 antibody and ovalbumin (OVA) as a model antigen to induce antigen-specific T-cell responses and antitumor responses were analyzed.
RESULTS: OVA-loaded NP conjugated with immunostimulatory CpG-oligonucleotides and anti-DEC205 antibody efficiently targeted and activated CD8+ DC in vivo, and induced strong OVA-specific T-cell activation. Vaccination of B16/OVA tumor-burdened mice with this NP formulation resulted in tumor growth arrest.
CONCLUSION: CD8+ DC-targeting trifunctional nanocarriers bear significant potential for antitumor immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 11(2016), 20 vom: 13. Okt., Seite 2647-2662 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shen, Limei [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 22.03.2018 Date Revised 22.03.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM264339673 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM264339673 | ||
| 003 | DE-627 | ||
| 005 | 20231224205854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0881.xml |
| 035 | |a (DE-627)NLM264339673 | ||
| 035 | |a (NLM)27628310 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shen, Limei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2018 | ||
| 500 | |a Date Revised 22.03.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: We wanted to assess the potency of a trifunctional nanoparticle (NP) that targeted and activated CD8+ dendritic cells (DC) and delivered an antigen to induce antitumor responses | ||
| 520 | |a MATERIALS & METHODS: The DC targeting and activating properties of ferrous NPs conjugated with immunostimulatory CpG-oligonucleotides, anti-DEC205 antibody and ovalbumin (OVA) as a model antigen to induce antigen-specific T-cell responses and antitumor responses were analyzed | ||
| 520 | |a RESULTS: OVA-loaded NP conjugated with immunostimulatory CpG-oligonucleotides and anti-DEC205 antibody efficiently targeted and activated CD8+ DC in vivo, and induced strong OVA-specific T-cell activation. Vaccination of B16/OVA tumor-burdened mice with this NP formulation resulted in tumor growth arrest | ||
| 520 | |a CONCLUSION: CD8+ DC-targeting trifunctional nanocarriers bear significant potential for antitumor immunotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CTL | |
| 650 | 4 | |a CpG | |
| 650 | 4 | |a DEC205 | |
| 650 | 4 | |a IFN-γ | |
| 650 | 4 | |a MDSC | |
| 650 | 4 | |a TNF-α | |
| 650 | 4 | |a dendritic cell | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a targeting | |
| 650 | 4 | |a tumor therapy | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a CD8 Antigens |2 NLM | |
| 650 | 7 | |a DEC-205 receptor |2 NLM | |
| 650 | 7 | |a Dextrans |2 NLM | |
| 650 | 7 | |a Fluorescent Dyes |2 NLM | |
| 650 | 7 | |a Lectins, C-Type |2 NLM | |
| 650 | 7 | |a Magnetite Nanoparticles |2 NLM | |
| 650 | 7 | |a Minor Histocompatibility Antigens |2 NLM | |
| 650 | 7 | |a Oligonucleotides |2 NLM | |
| 650 | 7 | |a Receptors, Cell Surface |2 NLM | |
| 650 | 7 | |a Ovalbumin |2 NLM | |
| 650 | 7 | |a 9006-59-1 |2 NLM | |
| 700 | 1 | |a Krauthäuser, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Hobernik, Dominika |e verfasserin |4 aut | |
| 700 | 1 | |a Abassi, Yasmin |e verfasserin |4 aut | |
| 700 | 1 | |a Dzionek, Andrzej |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolaev, Alexej |e verfasserin |4 aut | |
| 700 | 1 | |a Voltz, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Diken, Mustafa |e verfasserin |4 aut | |
| 700 | 1 | |a Krummen, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Montermann, Evelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Tubbe, Ingrid |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenz, Steffen |e verfasserin |4 aut | |
| 700 | 1 | |a Strand, Dennis |e verfasserin |4 aut | |
| 700 | 1 | |a Schild, Hansjörg |e verfasserin |4 aut | |
| 700 | 1 | |a Grabbe, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Bros, Matthias |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 11(2016), 20 vom: 13. Okt., Seite 2647-2662 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2016 |g number:20 |g day:13 |g month:10 |g pages:2647-2662 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2016 |e 20 |b 13 |c 10 |h 2647-2662 | ||